The Globe and Mail
🏢 Globe and Mail Inc. (Woodbridge)
Aug 3, 2026
· 5 min read
AI Analyzed
○ Unverifiable
View full audit trail →
AstraZeneca investors punish firm over reports of $400-billion Bristol Myers pharma deal
Original article ↗ 🔒 Paywalled source — limited preview availableB.I.A.S. ANALYSIS
CENTER
LEFTCENTERRIGHT
Signal breakdown
Heuristic (v1/v3)
-0.80 · LEFT
ML v2 (DistilBERT)
0.280 · RIGHT
Ensemble
0.140 · CENTER
🏦 Source Intelligence
Rolling outlet bias
CENTER
avg -0.080
9,037 articles tracked
7-day bias trend
LcenterR
V.E.R.I.F.Y. has fact-checked this article.
Subscribe to see claim-by-claim verdicts and reasoning.
Subscribe to see claim-by-claim verdicts and reasoning.
Article Excerpt
AstraZeneca investors punish firm over reports of $400-billion Bristol Myers pharma deal
MAGGIE FICK
REUTERS
PUBLISHED 1 HOUR AGO
Open this photo in gallery:
AstraZeneca's North America headquarters in Wilmington, Delaware in March, 2021.
RACHEL WISNIEWSKI/REUTERS
COMMENTS
SHARE
SAVE FOR LATER
Listen to this article
Learn more about audio
Log in or create a free account to listen to this article.
AstraZeneca AZN-N -6.88%
decrease
investors punished the pharmaceutical firm on Monday over reports of merger talks with U.S. rival Bristol Myers Squibb that could make one of the world’s bigge…
Read full article at The Globe and Mail ↗
How we scored this article
WTF uses a two-tier system: every article gets a heuristic bias score from keyword analysis, and priority articles (high overlap across 3+ outlets or strong heuristic signal) get full LLM analysis from B.I.A.S. and V.E.R.I.F.Y.
Analyzed by
B.I.A.S.
V.E.R.I.F.Y.
L.O.C.A.L.
quick v1 + full
Aug 3, 2026